Related Articles for PubMed (Select 16762076)

Nucleotide supplementation: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome [ISRCTN67764449].

Dancey CP, Attree EA, Brown KF.

Nutr J. 2006 Jun 8;5:16.

PMID: 16762076 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

11:

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.

Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR.

Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904.

PMID: 12656692 [PubMed - indexed for MEDLINE]

12:

Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome.

Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM.

Nurs Res. 2007 Nov-Dec;56(6):399-406.

PMID: 18004186 [PubMed - indexed for MEDLINE]

13:

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.

Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR.

Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.

PMID: 10468696 [PubMed - indexed for MEDLINE]

14:

A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.

Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.

Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. Epub 2008 Mar 4.

PMID: 18387426 [PubMed - indexed for MEDLINE]

15:

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID: 15654790 [PubMed - indexed for MEDLINE]

16:

The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.

Bardhan KD, Forbes A, Marsden CL, Mason T, Short G.

Aliment Pharmacol Ther. 2004 Jul 15;20(2):213-22.

PMID: 15233702 [PubMed - indexed for MEDLINE]

17:

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.

George AM, Meyers NL, Hickling RI.

Aliment Pharmacol Ther. 2008 May;27(9):830-7. Epub 2008 Feb 14.

PMID: 18284648 [PubMed - indexed for MEDLINE]

18:

Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.

Chang FY, Lu CL, Chen CY, Luo JC.

J Gastroenterol Hepatol. 2007 Dec;22(12):2266-72. Epub 2007 Jun 7.

PMID: 17559369 [PubMed - indexed for MEDLINE]

19:

Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients.

Mearin F, Badía X, Balboa A, Benavent J, Caballero AM, Domínguez-Muñoz E, Garrigues V, Piqué JM, Roset M, Cucala M, Figueras M; The RITMO Group.

Aliment Pharmacol Ther. 2006 Mar 15;23(6):815-26.

PMID: 16556184 [PubMed - indexed for MEDLINE]

20:

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID: 11485506 [PubMed - indexed for MEDLINE]

Recent Activity